Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Georgian Med News ; (272): 153-157, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29227276

ABSTRACT

Cystic fibrosis (CF) is the autosomal-recessive disorder caused by mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR). The Airway inflammation plays a central role in the progression of CF disease. Cystic fibrosis characterized by the overproduction of the pro-inflammatory cytokines and reduced expression of anti-inflammatory cytokines. Although the mechanisms of abnormal cytokine expression is still poorly understood, altered epigenetic regulations in T cells might contribute. In the present study we examined the expression of IFN-γ and IL-10 by CF T cells prior to and following 5-azaC treatment. In addition we investigated DNMTs levels in nuclear extracts of CD4+ T cells derived from CF and non-CF individuals. Seven CF patients (age: 5-12 years) were included in the study and compared to six age-matched healthy subjects (age: 6- 13 years). CD4+ T cells were isolated from PBMC using CD4 MicroBead kit (Miltenyi Biotec GmbH) and were cultured in RPMI 1640 medium at 37°C with 5% CO2, in presence or absence of 5-azacytidine. Concentrations of IL-10 and γ-INF in CD4+ T Cells were measured by ELISA (eBoiscience, san Diego, CA, USA). In our study we showed that 5 Azacytidine alters nuclear levels of DNMT 3a as well as modulates cytokine levels in CD4+ T cells derived from CF patients. After 5-azaC treatment secretion of IFN-γ was significantly decreased in CF T cells, while amount of IL-10 was elevated by ~2.5 times compared to untreated controls (P<0.05). In summary, data presented in this report demonstrates that epigenetic mechanisms such as DNA methylation may be considered as a one of the potential therapeutic target in a treatment of Cystic Fibrosis.


Subject(s)
Azacitidine/therapeutic use , Cystic Fibrosis/drug therapy , Cytokines/metabolism , DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors , DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors , T-Lymphocytes/drug effects , Adolescent , Case-Control Studies , Child , Child, Preschool , Cystic Fibrosis/metabolism , DNA (Cytosine-5-)-Methyltransferase 1/metabolism , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methyltransferase 3A , Humans , T-Lymphocytes/metabolism
2.
Burns Incl Therm Inj ; 12(3): 184-7, 1986 Feb.
Article in English | MEDLINE | ID: mdl-2423204

ABSTRACT

The administration of drugs influencing disordered haemostasis (heparin, nicotinic acid, thrental, phytin and alpha-tocopherol) to patients with burn injuries caused a 43 per cent shortening of the period of treatment. Necrotic eschar separated 7-9 days earlier and the periods necessary to prepare the burn wounds for surgical repair were shortened by 5 days. The success of skin grafting was enhanced with an increased percentage of attachment of the grafts. Necrotic changes of the mucosa of the gastrointestinal tract were found in 35 per cent of patients treated with the drugs as compared with 60 per cent of patients treated by the usual methods.


Subject(s)
Burns/drug therapy , Hemostasis/drug effects , Adolescent , Adult , Antithrombin III , Aprotinin/therapeutic use , Burns/blood , Drug Therapy, Combination , Female , Fibrin Fibrinogen Degradation Products , Heparin/therapeutic use , Humans , Male , Microcirculation/drug effects , Middle Aged , Niacin/therapeutic use , Pentoxifylline/therapeutic use , Phytic Acid/therapeutic use , Time Factors , Vitamin E/therapeutic use , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL